证券代码:002880 证券简称:卫光生物 公告编号:2023-046 深圳市卫光生物制品股份有限公司 深圳市卫光生物制品股份有限公司（以下简称公司）第三届董事会第十九次 会议决定于 2023 年 9 月 15 日在广东省深圳市光明区光明街道光侨大道 3402 号 公司综合楼 4 楼会议室召开 2023 年第三次临时股东大会（以下简称本次股东大 会）。现就召开本次股东大会有关事宜通知如下： 一、召开会议的基本情况 1.股东大会届次：2023 年第三次临时股东大会。 2.股东大会的召集人：公司董事会。 3.会议召开的合法合规性：公司第三届董事会第十九次会议审议通过《关于 召开 2023 年第三次临时股东大会的议案》，决定召开公司 2023 年第三次临时股 东大会。本次股东大会的召开符合有关法律法规和《公司章程》的规定。 4.会议召开的日期、时间： （1）现场会议召开时间：2023 年 9 月 15 日（星期五）15:00。 （2）网络投票时间： 2023 年第三次临时股东大会通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 （3）公司聘请的律师； （4）根据 ...

（1）报告期内，公司不存在控股股东及其他关联方占用公司资金的情况； （2）报告期内，公司无对外担保情况，不存在为控股股东及其他关联方、 任何非法人单位或个人提供担保的情形。 特此说明。 深圳市卫光生物制品股份有限公司 独立董事关于控股股东及其他关联方占用公司资金、公司对外 担保情况的专项说明和独立意见 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要 求》（证监会公告〔2022〕26 号）、《深圳证券交易所股票上市规则》等的规定， 作为深圳市卫光生物制品股份有限公司（以下简称公司）的独立董事，我们对公 司报告期内（2023 年 1 月 1 日至 2023 年 6 月 30 日）控股股东及其他关联方占 用公司资金情况和公司对外担保情况进行了认真的了解和查验，相关说明及独立 意见如下： 独立董事：汪新民、杨新发、王艳梅 2023 年 8 月 23 日 ...

证券代码:002880 证券简称:卫光生物 公告编号:2023-040 深圳市卫光生物制品股份有限公司 第三届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市卫光生物制品股份有限公司（以下简称公司）第三届董事会第十八次 会议于2023年8月17日在深圳市光明区光侨大道3402号公司办公楼四楼以现场结 合通讯方式召开。本次会议应参加董事8名，实际参加董事8名，公司部分监事及 高级管理人员列席了会议。本次会议由董事长张战先生主持，会议的召集、召开 和表决程序符合《公司法》等有关法律、法规及《公司章程》的规定。 二、董事会会议审议情况 会议经逐项审议，书面表决，审议通过了以下议案： 表决结果：同意票8票，反对票0票，弃权票0票。 三、备查文件 审议通过了《关于补选第三届董事会审计委员会委员的议案》。 鉴于张信先生业已退休，并已辞去公司董事、董事会审计委员会委员等职务， 为保障公司董事会审计委员会正常有序开展工作，根据《公司章程》及《审计委 员会工作细则》等的规定，董事会经审议同意补选董事李莉刚先生为公司第三届 ...

证券代码：002880 证券简称：卫光生物 深圳市卫光生物制品股份有限公司 投资者关系活动记录表 编号：2023-004 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员 | 线上参与公司2022年度网上业绩说明会的全体投资者 | | 姓名 | | | 时间 | 2023年05月16日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/） | | 上市公司接待人员姓名 | 董事长、董事会秘书（代行） 张战先生 | | | 董事、总经理 郭采平女士 | | | 董事、财务总监 岳章标先生 | | | 独立董事 王艳梅女士 公司2022年度业绩说明会采用网络文字互动的方式 | | | 1.请简单介绍一下公司的主要产品 | | | 召开，主要内容如下： | | | 答：尊敬的投资者，您好！公司目前共计拥有人血 | | 投资者关系活动主要 内容介绍 | 白蛋白 ...

Financial Performance - The company's operating revenue for 2022 was ¥667,931,462.81, a decrease of 26.39% compared to ¥907,434,715.73 in 2021[22] - The net profit attributable to shareholders for 2022 was ¥117,443,567.69, down 42.83% from ¥205,436,658.57 in the previous year[22] - The net profit after deducting non-recurring gains and losses was ¥101,133,456.51, a decline of 48.68% from ¥197,069,666.27 in 2021[22] - The basic earnings per share for 2022 was ¥0.5178, representing a decrease of 42.84% compared to ¥0.9058 in 2021[22] - Total revenue for blood products was CNY 653,934,311, a decrease of 26.47% year-on-year, with a gross margin of 35.23%[60] - Revenue from blood products amounted to ¥653,934,311.64, accounting for 97.90% of total revenue, with a decline of 26.47% from ¥889,291,075.59 in the previous year[58] - The company reported a significant reduction in financial expenses, down 74.81% to CNY -1,473,091.67, due to reclassification of interest income[67] - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year growth of 12%[135] Assets and Liabilities - Total assets at the end of 2022 amounted to ¥2,575,733,822.26, an increase of 28.56% from ¥2,003,504,959.66 at the end of 2021[22] - The net assets attributable to shareholders at the end of 2022 were ¥1,840,809,066.12, up 4.08% from ¥1,768,725,498.43 in 2021[22] - The company reported a significant increase in long-term borrowings to ¥428,961,954.68, attributed to fixed asset loans[76] - Short-term borrowings rose to ¥100,086,111.11, reflecting new short-term loans taken during the period[76] - Inventory levels increased to ¥605,510,451.16, representing 23.51% of total assets, driven by higher raw materials and finished goods[76] Cash Flow - The net cash flow from operating activities for 2022 was ¥1,199,043.12, a significant decrease of 99.51% compared to ¥246,886,601.24 in 2021[22] - The net cash flow from investment activities increased by 67.98%, primarily due to increased payments for construction projects[72] - The company reported a net cash flow from operating activities of CNY 52.32 million in the fourth quarter, a turnaround from negative cash flows in the first three quarters[27] Research and Development - The company has established a comprehensive product R&D mechanism, with 41 national authorized patents, including 17 invention patents and 24 utility model patents[52] - Research and development expenses decreased by 24.63% to CNY 35,865,911.95, primarily due to reduced investment in R&D[67] - The R&D expenditure for new products and technologies was 200 million RMB, accounting for 13.3% of total revenue[135] - The company is committed to enhancing its R&D capabilities by improving management mechanisms and optimizing R&D models[106] Market and Competition - The blood products market in China was valued at approximately CNY 40 billion in 2022, with significant growth potential driven by increasing healthcare demands and an aging population[37] - The company aims to expand its market presence by leveraging its technological and brand advantages to drive product exports and explore international markets[40] - Increased competition in the market is anticipated as companies focus on developing products like human fibrinogen and recombinant factor VIII, necessitating optimized marketing strategies and international market exploration[108] Corporate Governance - The company has established effective communication channels with shareholders to ensure their rights are upheld[112] - The company held its first temporary shareholders' meeting on March 24, 2022, with an investor participation rate of 65.36%[126] - The board of directors and management team have remained stable, with no reported changes in senior management during the reporting period[127] - The company has established a comprehensive internal control system that covers all business activities and financial reporting, with no significant omissions identified[160] Environmental and Social Responsibility - The company has complied with all relevant environmental protection laws and obtained necessary permits for its production projects[168] - The company reported no instances of exceeding pollution discharge limits in its operations[169] - The company has contributed a total of 846,100 RMB to poverty alleviation efforts, including 504,800 RMB for educational donations and 221,300 RMB for purchasing agricultural products from supported areas[180] - The company actively engages in social welfare activities, with nearly 150 registered volunteers contributing over 1,400 service hours[179] Future Plans and Strategies - The company plans to launch new products, including human prothrombin complex and human factor VIII, expected to be approved for sale in 2023, which will enhance the utilization rate of raw plasma[68] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[135] - The company aims to leverage capital markets for development, including targeted stock issuance and acquisitions of quality assets in the industry[102] - The company plans to enhance its product portfolio with new vaccines and therapies, which are expected to strengthen its competitive position and overall profitability[69]

Financial Performance - The company's revenue for Q1 2023 was CNY 208,518,007.07, representing a 51.34% increase compared to CNY 137,783,337.47 in the same period last year[4] - Net profit attributable to shareholders was CNY 45,736,044.33, an increase of 80.54% from CNY 25,333,345.87 year-on-year[4] - Basic earnings per share rose to CNY 0.2017, up 80.57% from CNY 0.1117 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached ¥208,518,007.07, a significant increase of 51.2% compared to ¥137,783,337.47 in Q1 2022[16] - Net profit for Q1 2023 was ¥45,625,876.61, representing a 80.9% increase from ¥25,205,287.60 in Q1 2022[17] - Earnings per share (EPS) for Q1 2023 was ¥0.2017, compared to ¥0.1117 in the same period last year, reflecting a 80.5% increase[18] - The total comprehensive income for Q1 2023 was ¥45,625,876.61, compared to ¥25,205,287.60 in Q1 2022, showing a strong growth trajectory[18] Cash Flow - The net cash flow from operating activities reached CNY 51,288,202.98, a significant improvement from a negative CNY 5,378,157.74 in the previous year, marking a 1,053.64% increase[4] - Cash inflow from operating activities totaled ¥258,633,808.51, an increase from ¥182,856,172.52 in Q1 2022[19] - The net cash flow from operating activities for Q1 2023 was ¥51,288,202.98, compared to a negative cash flow of ¥5,378,157.74 in the same period last year[20] - The net cash flow from investing activities was negative at ¥81,871,610.61, a decrease from the previous year's negative cash flow of ¥56,440,030.96[20] - The net cash flow from financing activities was positive at ¥47,169,380.45, down from ¥162,125,824.98 in Q1 2022[20] - The net increase in cash and cash equivalents for Q1 2023 was ¥16,585,972.82, compared to an increase of ¥100,307,636.28 in Q1 2022[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,656,276,378.90, a 3.13% increase from CNY 2,575,733,822.26 at the end of the previous year[4] - Total assets as of March 31, 2023, amounted to ¥2,656,276,378.90, up from ¥2,575,733,822.26 at the beginning of the year, indicating a growth of about 3.1%[14] - Total liabilities decreased from ¥229,755,503.63 to ¥211,557,179.25, a reduction of approximately 7.9%[14] - Total liabilities increased to ¥743,116,795.21 from ¥708,199,697.29, reflecting a growth of 4.9% year-over-year[17] - Total equity attributable to shareholders reached ¥1,886,545,110.45, up from ¥1,840,809,066.12, marking a growth of 2.5%[17] Operating Costs and Income - The company reported a 54.51% increase in operating costs, totaling CNY 121,477,101.04, primarily due to increased sales volume[6] - Operating costs amounted to ¥155,644,988.93, up 42.3% from ¥109,391,163.31 in the previous year, with operating costs per revenue decreasing[16] - Other income increased by 42.48% to CNY 2,634,046.04, mainly due to higher government subsidies received[7] - The company reported a significant increase in other income to ¥2,634,046.04 from ¥1,848,731.39, indicating improved financial performance[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 10,140[9] - The largest shareholder, Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau, holds 65.25% of shares, totaling 147,987,000 shares[9] - The company has no preferred shareholders as of the reporting period[11] Research and Development - Research and development expenses were ¥10,819,588.91, slightly up from ¥10,460,066.69 in the previous year, indicating continued investment in innovation[16] Other Information - The company has initiated a share acquisition plan as of January 10, 2023, and a non-public stock issuance plan on March 30, 2023[11] - The first phase employee stock ownership plan holds 820,890 shares, representing a small portion of the total shares[10] - The company did not conduct an audit for the Q1 2023 report[21] - The report was presented by the board of directors on April 24, 2023[22]

深圳市卫光生物制品股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳市卫光生物制品股份有限公司（以下简称公司）2022 年年度报告已于 2023 年 4 月 26 日刊登于巨潮资讯网(www.cninfo.com.cn)。为便于广大投资者更 加全面深入地了解公司 2022 年度经营业绩、发展战略等情况，公司拟于 2023 年 5 月 16 日（星期二）举办业绩说明会。具体情况如下： 一、网上业绩说明会的安排 证券代码:002880 证券简称:卫光生物 公告编号:2023-023 （一）会议召开时间：2023 年 5 月 16 日（星期二）15:00-17:00 （二）会议召开方式：网络互动方式 （三）会议召开网址：价值在线(www.ir-online.cn) （四）出席本次业绩说明会的人员：公司董事长、董事会秘书（代行）张战 先生；董事、总经理郭采平女士；董事、财务总监岳章标先生；独立董事王艳梅 女士。 二、征集问题事项及投资者参加方式 投资者可于2023年5月16日15:00-17:00通过网址h ...

Group 1: Company Overview and Competitive Advantages - The company ranks among the industry leaders in average plasma collection volume per station in 2021, with a high blood plasma utilization rate and strong operational capabilities [2] - In 2022, the company signed a cooperation agreement with the Russian government for the production and technology transfer of human blood albumin and intravenous immunoglobulin [2] - The company is focused on building the "Weiguang" brand, which has gained market recognition for its product quality [2] - The Weiguang Life Science Park aims to establish a diversified biopharmaceutical platform, targeting the global forefront of biotechnology [3] Group 2: Weiguang Life Science Park Development - The park is positioned to leverage the Greater Bay Area and Shenzhen's dual-zone drive, focusing on synthetic biology and neuroscience as key areas [3] - It aims to create a research economic ecosystem characterized by innovation incubation and achievement transformation [3] - The park will support the growth of innovative projects and establish a health ecosystem by linking industry resources [3] Group 3: Product Pricing and Production Capacity - The company maintains stable factory prices for its main products, such as human blood albumin and intravenous immunoglobulin, with minimal fluctuations [3] - Following a technological transformation of production lines in 2022, the company has seen a slight increase in plasma collection volume in the first half of 2022 [3] - The Pingguo plasma station, located in Guangxi, has achieved leading industry collection volumes due to effective local donor engagement strategies [3] Group 4: Future Plans and Expansion - The Ankang plasma station will commence operations as soon as it obtains the necessary licenses [3] - The company has plans to establish new plasma stations during the 14th Five-Year Plan period [3]